HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.

AbstractBACKGROUND & AIMS:
Budesonide is effective in treating collagenous colitis, but no treatment is established for lymphocytic colitis. We performed a randomized, double-blind, placebo-controlled study to evaluate the effects of budesonide in patients with lymphocytic colitis.
METHODS:
Forty-two patients (median age, 61 years) with lymphocytic colitis and chronic diarrhea were randomly assigned to groups that were given oral doses of budesonide (9 mg/d) or placebo for 6 weeks. Nonresponders at week 6 were given open-label budesonide (9 mg/d) for 6 additional weeks. A complete colonoscopy and histologic and quality-of-life analyses were performed at baseline and at week 6. The primary end point was clinical remission at 6 weeks, with last observation carried forward (LOCF). All patients who left the study in clinical remission were followed for relapse.
RESULTS:
At week 6, 86% of patients given budesonide were in clinical remission (with LOCF) compared with 48% of patients given placebo (P = .010). Furthermore, open-label budesonide therapy induced clinical remission in 7 of 8 patients given placebo. Histologic remission was observed in 73% of patients given budesonide compared with 31% given placebo (P = .030). Only 1 patient discontinued budesonide therapy prematurely. During a mean follow-up period of 14 months, 15 patients (44.1%) experienced a clinical relapse (after a mean of 2 months); 8 of the relapsing patients were retreated with and responded again to budesonide.
CONCLUSIONS:
Budesonide effectively induces clinical remission in patients with lymphocytic colitis and significantly improves histology results after 6 weeks. Clinical relapses occur but can be treated again with budesonide.
AuthorsStephan Miehlke, Ahmed Madisch, Diana Karimi, Susann Wonschik, Eberhard Kuhlisch, Renate Beckmann, Andrea Morgner, Ralph Mueller, Roland Greinwald, Gerhard Seitz, Gustavo Baretton, Manfred Stolte
JournalGastroenterology (Gastroenterology) Vol. 136 Issue 7 Pg. 2092-100 (Jun 2009) ISSN: 1528-0012 [Electronic] United States
PMID19303012 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Glucocorticoids
  • Budesonide
Topics
  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy, Needle
  • Budesonide (administration & dosage, adverse effects)
  • Colitis, Lymphocytic (drug therapy, pathology)
  • Colonoscopy (methods)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Germany
  • Glucocorticoids (administration & dosage, adverse effects)
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Probability
  • Quality of Life
  • Recurrence
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: